The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes

This publication has 10 references indexed in Scilit:

• Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
  New England Journal of Medicine, 2001
• Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)
  Published by Oxford University Press (OUP) ,1999
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
  Circulation, 1999
• Presence of Tissue Factor Pathway Inhibitor in Human Atherosclerotic Plaques Is Associated With Reduced Tissue Factor Activity
  Circulation, 1998
• A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
  New England Journal of Medicine, 1997
• Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
  Circulation, 1997
• Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11A
  Journal of the American College of Cardiology, 1997
• Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic Plaques
  Circulation, 1997
• Identification of Active Tissue Factor in Human Coronary Atheroma
  Circulation, 1996
• Low-molecular-weight heparin during instability in coronary artery disease
  The Lancet, 1996